论文部分内容阅读
目的评价那格列奈与甘精胰岛素联合治疗2型糖尿病(T2DM)患者的疗效及耐受性。方法57例60岁以上T2DM患者住院应用那格列奈与甘精胰岛素联合治疗,评估其空腹血糖、餐后血糖及糖化血红蛋及血糖波动情况。结果那格列奈与甘精胰岛素联合治疗后早餐前、午餐后2 h、晚餐后2 h及睡前平均血糖较治疗前明显下降(P<0.05);早餐后2 h及午餐前血糖较治疗前降低明显(P<0.01);晚餐前、凌晨3时血糖值较治疗前有降低趋势(P>0.05)。结论那格列奈与甘精胰岛素合用可安全有效地用于60岁以上T2DM患者的治疗。
Objective To evaluate the efficacy and tolerability of nateglinide and insulin glargine in patients with type 2 diabetes mellitus (T2DM). Methods 57 patients with T2DM over 60 years of age were hospitalized with nateglinide and insulin glargine combined treatment to assess the fasting blood glucose, postprandial blood glucose and glycosylated hemoglobin and blood glucose fluctuations. Results Compared with before treatment, nateglinide and glargine combined treatment before breakfast, 2 h after lunch, 2 h after dinner and before going to bed significantly lower than before treatment (P <0.05); 2 h after breakfast and before meals blood glucose treatment (P <0.01). The blood glucose level before dinner and before 3:00 was lower than before treatment (P> 0.05). Conclusions Nateglinide and insulin glargine are safe and effective for the treatment of T2DM patients over the age of 60 years.